Literature DB >> 11749665

Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis.

Giovanni Sansoè1, Alberto Ferrari, Carmen Nives Castellana, Lorenzo Bonardi, Erica Villa, Federico Manenti.   

Abstract

Cimetidine inhibits the tubular secretion of creatinine, without altering the glomerular filtration rate (GFR). During cimetidine administration the creatinine/inulin clearance ratio approaches unity in patients with renal failure. We determined the clearance of lithium (an index of fluid delivery to the distal nephron), inulin (a measure of the actual GFR) and creatinine during cimetidine administration to investigate the occurrence of tubular creatinine secretion in patients with compensated cirrhosis. A total of 12 patients with Child-Pugh A cirrhosis were studied initially. The subjects consumed a stable diet containing 100 mmol of sodium. On successive days, 9 h creatinine clearances were measured, first without and then with the oral administration of cimetidine (400 mg as a priming dose, followed by 200 mg every 3 h). During the first study day, 4 h renal lithium clearance was also calculated. A further group of five patients with fully compensated cirrhosis underwent the measurement (on successive days) of plasma inulin clearance, first without and then with the oral administration of cimetidine (same schedule of drug administration). Cimetidine administration unmasked a marked overestimation of GFR when calculated as creatinine clearance (baseline, 138+/-20 ml/min; +cimetidine, 89+/-13 ml/min; P<0.01). Consequently, during cimetidine administration the calculated lithium fractional excretion (a measure of the fraction of filtered sodium load that is delivered to the loop of Henle) rose from 21.4+/-13.2% to 32.3+/-18.9% (P<0.05), and the ratio between absolute distal tubular sodium reabsorption and filtered sodium load rose from 20.6+/-13.1% to 31.6+/-19.3% (P<0.01). Cimetidine caused no significant decrease in the actual GFR (i.e. inulin clearance) when administered to the second group of patients with compensated cirrhosis. Our data demonstrate significant tubular secretion of creatinine in patients with compensated cirrhosis and, consequently, a marked overestimation of GFR and filtered sodium load and an underestimation of the fractional distal tubular sodium reabsorption when these parameters are calculated by means of the traditional creatinine and lithium clearance computation. The true GFR (measured as inulin clearance) is unaffected by cimetidine administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11749665

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

Review 1.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.

Authors:  Volker Vallon; Satish A Eraly; Satish Ramachandra Rao; Maria Gerasimova; Michael Rose; Megha Nagle; Naohiko Anzai; Travis Smith; Kumar Sharma; Sanjay K Nigam; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

3.  Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.

Authors:  Giuliano Ciarimboli; Cynthia S Lancaster; Eberhard Schlatter; Ryan M Franke; Jason A Sprowl; Hermann Pavenstädt; Vivian Massmann; Denise Guckel; Ron H J Mathijssen; Wenjian Yang; Ching-Hon Pui; Mary V Relling; Edwin Herrmann; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2012-01-05       Impact factor: 12.531

Review 4.  Cystatin C as a potential biomarker for dosing of renally excreted drugs.

Authors:  Nguessan Aimé Brou; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 5.  Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.

Authors:  Juan Carlos Q Velez
Journal:  Kidney360       Date:  2021-12-03

6.  The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.

Authors:  Y-L He; R Sabo; J Campestrini; Y Wang; M Ligueros-Saylan; K C Lasseter; S C Dilzer; D Howard; W P Dole
Journal:  Eur J Clin Pharmacol       Date:  2007-05-08       Impact factor: 2.953

7.  Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.

Authors:  Andrea N Edginton; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Major contribution of tubular secretion to creatinine clearance in mice.

Authors:  Christoph Eisner; Robert Faulhaber-Walter; Yaohui Wang; Asada Leelahavanichkul; Peter S T Yuen; Diane Mizel; Robert A Star; Josephine P Briggs; Mark Levine; Jurgen Schnermann
Journal:  Kidney Int       Date:  2009-12-23       Impact factor: 10.612

10.  Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.

Authors:  Stefan Willmann; Katrin Coboeken; Stefanie Kapsa; Kirstin Thelen; Markus Mundhenke; Kerstin Fischer; Burkhard Hügl; Wolfgang Mück
Journal:  J Clin Pharmacol       Date:  2021-01-06       Impact factor: 3.126

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.